A Phase 3 interventional study of Bimekizumab and Placebo in Nonradiographic Axial Spondyloarthritis, sponsored by UCB Biopharma SRL. Completed at 83 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Axial Spondyloarthritis by UCB S.A. — 2 open to participants now, 2 under way, none of them phase 3. Axial Spondyloarthritis · UCB S.A..
Among the 13 studies in Axial Spondyloarthritis by UCB S.A., this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2019, is one of 5 in phase 3, and was the 8th registered.
186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.
Browse Axial Spondyloarthritis studies →2 of the 13 studies in Axial Spondyloarthritis by UCB S.A. are open now, in 9 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Bulgaria, Czechia and 3 more countries
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, Germany and 2 more countries
Ages 18+ · Women only
By country, each count listing its studies:
Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 274 is above the median of 108 across 122 interventional studies indexed under Axial Spondyloarthritis.
Median enrollment 274 across the 11 interventional studies, 341 across the 2 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Axial Spondyloarthritis by UCB S.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient has nonradiographic axial spondyloarthritis (nr-axSpA) with all of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
Drug: Bimekizumab
Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
Drug: Bimekizumab · Other: Placebo
Subjects will receive bimekizumab at pre-specified time-points.
Also known as: BKZ, UCB4940
Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
Also known as: PBO
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16
ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity; and no worsening at all in the remaining component.
Time frame: Week 16
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Subjects at Week 16
ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity; and no worsening at all in the remaining component.
Time frame: Week 16
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16
BASDAI is a well-established patient-reported endpoint assessing severity of AS symptoms. It is made of 6 items assessing severity of fatigue, spinal pain, peripheral joint pain \& swelling, enthesitis, \& morning stiffness (both severity and duration). Each question is rated using a numerical rating scale ranging from 0 (none) to 10 (very severe), higher score=higher symptom severity.BASDAI score is calculated by computing mean of questions 5 and 6 \& adding it to sum of questions 1 to 4.This score is then divided by 5.Total BASDAI score ranges from 0=no disease activity to 10=maximal disease activity, higher score indicates higher symptom severity. A negative change reflects improvement.
Time frame: Baseline, Week 16
Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16
ASAS20 response is defined as relative improvements of at least 20% and absolute improvement of at least 1 unit in at least 3 of the 4 following components:1) PGADA assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities, 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI, each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity; and no worsening at all in the remaining component.
Time frame: Week 16
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16
The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of less than or equal to (\<=) 2 units in each of the 4 following components:1) PGADA assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity,2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities, and 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity.
Time frame: Week 16
Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16
ASDAS-MI is achieved when there is a reduction (improvement) greater or equal to (\>=) 2.0 in ASDAS relative to Baseline. ASDAS is calculated by adding the 5 following components: 1) 0.121 × Neck, back or hip pain (BASDAI Q2), 2) 0.058 × Duration of morning stiffness (BASDAI Q6), 3) 0.110 × Patient's Global Assessment of Disease Activity (PGADA), 4) 0.073 × Peripheral pain/swelling in joints (BASDAI Q3), 5) 0.579 × (natural logarithm of the C-reactive protein (CRP) \[mg/L\] + 1). Q2, Q3 and Q6 from BASDAI and PGADA, are all assessed on a numerical scale from 0 \[none / not active\] to 10 \[very severe / very active\]. There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 is assumed for values of hs-CRP below the lower limit of quantification (LLOQ)), but no defined upper score. Higher ASDAS scores reflect higher disease activity and participants achieving ASDAS-MI are considered to have a major improvement in their disease.
Time frame: Week 16
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16
ASAS 5/6 response is defined as achieving at least 20% improvement in 5 of the following 6 components:1) PGADA assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most intense pain\], higher score=higher pain intensity,3) BASFI assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \[none/ 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity;5) spinal mobility (ie, lateral spinal flexion component of Bath Ankylosing Spondylitis Disease Metrology Index) on a scale ranging from 0 \[no limitation of movement\] to 10 \[very severe limitation of movement\] and 6) high sensitivity C-reactive protein (hs-CRP).
Time frame: Week 16
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16
The BASFI is a well-established PRO measure of physical functioning used in AxSpA trials. It assesses participants' level of ability during the past week in conducting 10 physical activities on a scale ranging from 0 \[easy\] to 10 \[impossible\]. The BASFI score is the mean of the 10 item scores and ranges from 0 to 10, with lower scores indicating better physical function. A negative change in BASFI indicates improvement. The higher the negative value the better the improvement.
Time frame: Baseline, Week 16
Change From Baseline in Nocturnal Spinal Pain Score Using Numeric Rating Scale (NRS) at Week 16
Nocturnal spinal pain experienced by participants with axial spondyloarthritis (axSpA) was assessed on a numerical rating scale ranging from 0 (no pain) to 10 (most severe pain). A lower score indicates less pain and a negative change represents an improvement.
Time frame: Baseline, Week 16
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16
The Ankylosing Spondylitis Quality of Life (ASQoL) is an 18-item PRO measure developed specifically for measuring health-related quality of life (HRQoL) in participants with ankylosing spondylitis and validated in the full spectrum of axial spondyloarthritis (axSpA). Each item is given a score of 1 for positive responses indicating impaired quality of life, and a score of 0 for negative responses. All item scores are summed to generate the total score ranging from 0 to 18 with a higher score indicating worse HRQoL. A negative change represents an improvement.
Time frame: Baseline, Week 16
Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16
SF-36 is a 36-item HRQoL instrument with recall period of 4 weeks. Items are grouped into 8 domains: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) and 1 item for Health Transition during last year. PCS and Mental Component Summary (MCS) scores are calculated from 8 domains (excluding Health Transition item). Each of SF-36 derived raw scores range from 0 to 100; higher score = better function. PCS score is calculated from 8 domain scores. It is standardized score ranging from 7.3 to 70.1, with a mean of 50 and SD of 10 in general US population, higher values = better function, and positive change reflects improvement. A PCS score mean below 47 indicates impaired physical functioning. Individual respondent's score that falls outside T-score range of 45 to 55 are outside average general US population range.
Time frame: Baseline, Week 16
Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16
The BASMI characterizes the spinal mobility of participants with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis. It is a disease-specific measure consisting of 5 clinical measures to reflect participant axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the 5 scores provides the total BASMI score (ranging from 0 to 10). The higher the BASMI score, the more severe the participant's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value, the better the improvement.
Time frame: Baseline, Week 16
Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16
The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score reflects higher severity and a negative change represents an improvement.
Time frame: Baseline, Week 16
Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline
The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. Enthesitis free state is defined as having a MASES score of 0. A higher score reflects higher severity and a negative change represents an improvement.
Time frame: Baseline, Week 16
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety follow up (SFU)). TEAEs were analyzed and have been reported separately for Double-Blind Treatment Period (Safety set),Maintenance Period (MP) (Maintenance Set) and Overall Period (Safety set) which includes all participants who received BKZ 160 mg Q4W during the study. The overall period arm reports repeated TEAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, Maintenance Period (MP) included AEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.
Time frame: From Baseline (Day 1) until Safety-Follow-Up (up to Week 68) (Week 48 last IMP intake + 20 weeks SFU)
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study
A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in 1) Death, 2) Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), 3) Significant or persistent disability/incapacity, 4) Congenital anomaly/birth defect (including that occurring in a fetus), 5) Important medical event that, based upon appropriate medical judgment, may jeopardize the participant or participant may require medical or surgical intervention to prevent any of the above, 6) Initial inpatient hospitalization or prolongation of hospitalization. The overall period arm reports repeated SAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included SAEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.
Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 68)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study
TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). The overall period arm reports repeated events from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included events of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.
Time frame: From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)
The study started to enroll participants in April 2019 and concluded in April 2023. Among the total of 274 participants, 254 participants were enrolled under the global study protocol by June 2021, including 16 enrolled in China. The enrolment was extended in China to achieve the target of 36 participants as agreed with the local agency and additional 20 Chinese participants were enrolled by February 2022 in the China Extension population.
| Milestone | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) | BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population) |
|---|---|---|---|---|---|---|
| Started | 126 | 128 | 0 | 11 | 9 | 0 |
| Started chinese participants | 7 | 9 | 0 | 11 | 9 | 0 |
| Completed | 118 | 126 | 0 | 11 | 9 | 0 |
| Not completed | 8 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Patient compliance | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by study participant | 4 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) | BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 242 | 0 | 0 | 20 |
| Completed | 0 | 0 | 220 | 0 | 0 | 17 |
| Not completed | 0 | 0 | 22 | 0 | 0 | 3 |
| Withdrew: Withdrawal by study participant | 0 | 0 | 12 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 4 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 5 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Covid-19 pandemic situation & site restrictions | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Non- compliance | 0 | 0 | 0 | 0 | 0 | 1 |
ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity; and no worsening at all in the remaining component.
| percentage of participants | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16 | 21.4 | 47.7 | 27.3 | 33.3 |
ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity; and no worsening at all in the remaining component.
| percentage of Participants | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Subjects at Week 16 | 22.9 | 46.6 | 27.3 | 37.5 |
BASDAI is a well-established patient-reported endpoint assessing severity of AS symptoms. It is made of 6 items assessing severity of fatigue, spinal pain, peripheral joint pain \& swelling, enthesitis, \& morning stiffness (both severity and duration). Each question is rated using a numerical rating scale ranging from 0 (none) to 10 (very severe), higher score=higher symptom severity.BASDAI score is calculated by computing mean of questions 5 and 6 \& adding it to sum of questions 1 to 4.This score is then divided by 5.Total BASDAI score ranges from 0=no disease activity to 10=maximal disease activity, higher score indicates higher symptom severity. A negative change reflects improvement.
| score on a scale | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16 | -1.55 ± 0.22 | -3.07 ± 0.21 | -2.09 ± 0.564 | -2.99 ± 0.571 |
ASAS20 response is defined as relative improvements of at least 20% and absolute improvement of at least 1 unit in at least 3 of the 4 following components:1) PGADA assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities, 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI, each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity; and no worsening at all in the remaining component.
| percentage of participants | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16 | 38.1 | 68.8 | 54.5 | 44.4 |
The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of less than or equal to (\<=) 2 units in each of the 4 following components:1) PGADA assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity,2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most severe pain\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities, and 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \[none / 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity.
| percentage of participants | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16 | 7.1 | 25.8 | 9.1 | 33.3 |
ASDAS-MI is achieved when there is a reduction (improvement) greater or equal to (\>=) 2.0 in ASDAS relative to Baseline. ASDAS is calculated by adding the 5 following components: 1) 0.121 × Neck, back or hip pain (BASDAI Q2), 2) 0.058 × Duration of morning stiffness (BASDAI Q6), 3) 0.110 × Patient's Global Assessment of Disease Activity (PGADA), 4) 0.073 × Peripheral pain/swelling in joints (BASDAI Q3), 5) 0.579 × (natural logarithm of the C-reactive protein (CRP) \[mg/L\] + 1). Q2, Q3 and Q6 from BASDAI and PGADA, are all assessed on a numerical scale from 0 \[none / not active\] to 10 \[very severe / very active\]. There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 is assumed for values of hs-CRP below the lower limit of quantification (LLOQ)), but no defined upper score. Higher ASDAS scores reflect higher disease activity and participants achieving ASDAS-MI are considered to have a major improvement in their disease.
| percentage of participants | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16 | 7.1 | 27.3 | 9.1 | 11.1 |
ASAS 5/6 response is defined as achieving at least 20% improvement in 5 of the following 6 components:1) PGADA assessed on a scale ranging from 0 \[not active\] to 10 \[very active\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \[no pain\] to 10 \[most intense pain\], higher score=higher pain intensity,3) BASFI assessing participant's level of ability on a scale ranging from 0 \[easy\] to 10 \[impossible\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \[none/ 0 hour\] to 10 \[very severe / 2 or more hours\], higher score=higher severity;5) spinal mobility (ie, lateral spinal flexion component of Bath Ankylosing Spondylitis Disease Metrology Index) on a scale ranging from 0 \[no limitation of movement\] to 10 \[very severe limitation of movement\] and 6) high sensitivity C-reactive protein (hs-CRP).
| percentage of participants | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16 | 20.6 | 45.3 | 18.2 | 44.4 |
The BASFI is a well-established PRO measure of physical functioning used in AxSpA trials. It assesses participants' level of ability during the past week in conducting 10 physical activities on a scale ranging from 0 \[easy\] to 10 \[impossible\]. The BASFI score is the mean of the 10 item scores and ranges from 0 to 10, with lower scores indicating better physical function. A negative change in BASFI indicates improvement. The higher the negative value the better the improvement.
| score on a scale | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16 | -0.91 ± 0.22 | -2.39 ± 0.21 | -0.79 ± 0.340 | -2.03 ± 0.368 |
Nocturnal spinal pain experienced by participants with axial spondyloarthritis (axSpA) was assessed on a numerical rating scale ranging from 0 (no pain) to 10 (most severe pain). A lower score indicates less pain and a negative change represents an improvement.
| score on a scale | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Change From Baseline in Nocturnal Spinal Pain Score Using Numeric Rating Scale (NRS) at Week 16 | -1.71 ± 0.27 | -3.51 ± 0.25 | -2.41 ± 0.638 | -3.51 ± 0.658 |
The Ankylosing Spondylitis Quality of Life (ASQoL) is an 18-item PRO measure developed specifically for measuring health-related quality of life (HRQoL) in participants with ankylosing spondylitis and validated in the full spectrum of axial spondyloarthritis (axSpA). Each item is given a score of 1 for positive responses indicating impaired quality of life, and a score of 0 for negative responses. All item scores are summed to generate the total score ranging from 0 to 18 with a higher score indicating worse HRQoL. A negative change represents an improvement.
| score on a scale | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16 | -2.30 ± 0.43 | -4.94 ± 0.42 | 0.18 ± 0.970 | -1.66 ± 0.967 |
SF-36 is a 36-item HRQoL instrument with recall period of 4 weeks. Items are grouped into 8 domains: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) and 1 item for Health Transition during last year. PCS and Mental Component Summary (MCS) scores are calculated from 8 domains (excluding Health Transition item). Each of SF-36 derived raw scores range from 0 to 100; higher score = better function. PCS score is calculated from 8 domain scores. It is standardized score ranging from 7.3 to 70.1, with a mean of 50 and SD of 10 in general US population, higher values = better function, and positive change reflects improvement. A PCS score mean below 47 indicates impaired physical functioning. Individual respondent's score that falls outside T-score range of 45 to 55 are outside average general US population range.
| T-score | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16 | 5.36 ± 0.79 | 9.32 ± 0.76 | -3.52 ± 2.462 | 3.75 ± 2.364 |
The BASMI characterizes the spinal mobility of participants with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis. It is a disease-specific measure consisting of 5 clinical measures to reflect participant axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the 5 scores provides the total BASMI score (ranging from 0 to 10). The higher the BASMI score, the more severe the participant's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value, the better the improvement.
| score on a scale | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16 | -0.11 ± 0.08 | -0.44 ± 0.08 | 0.12 ± 0.211 | -0.38 ± 0.232 |
The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score reflects higher severity and a negative change represents an improvement.
| score on a scale | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16 | -1.11 ± 0.38 | -2.16 ± 0.37 | -1.35 ± 0.692 | -1.80 ± 0.871 |
The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. Enthesitis free state is defined as having a MASES score of 0. A higher score reflects higher severity and a negative change represents an improvement.
| percentage of participants | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) |
|---|---|---|---|---|
| Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline | 23.9 | 51.1 | 60.0 | 66.7 |
TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety follow up (SFU)). TEAEs were analyzed and have been reported separately for Double-Blind Treatment Period (Safety set),Maintenance Period (MP) (Maintenance Set) and Overall Period (Safety set) which includes all participants who received BKZ 160 mg Q4W during the study. The overall period arm reports repeated TEAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, Maintenance Period (MP) included AEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.
| percentage of participants | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population) | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) | BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population) | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study | 56.3 | 62.5 | 67.8 | 75.0 | 72.7 | 100 | 80.0 | 90.0 |
A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in 1) Death, 2) Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), 3) Significant or persistent disability/incapacity, 4) Congenital anomaly/birth defect (including that occurring in a fetus), 5) Important medical event that, based upon appropriate medical judgment, may jeopardize the participant or participant may require medical or surgical intervention to prevent any of the above, 6) Initial inpatient hospitalization or prolongation of hospitalization. The overall period arm reports repeated SAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included SAEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.
| percentage of participants | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population) | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) | BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population) | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study | 0.8 | 0 | 3.7 | 3.7 | 0 | 0 | 15.0 | 15.0 |
TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). The overall period arm reports repeated events from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included events of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.
| percentage of participants | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population) | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) | BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population) | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study | 4.0 | 1.6 | 2.5 | 3.3 | 0 | 0 | 0 | 0 |
Collected over From Baseline (Day 1) until Safety Follow-Up (up to Week 68). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (up to Week 16) (Global Population) | 0/126 (0%) | 1/126 (0.8%) | 30/126 (23.8%) |
| Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | 0/128 (0%) | 0/128 (0%) | 40/128 (31.3%) |
| Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population) | 0/242 (0%) | 9/242 (3.7%) | 94/242 (38.8%) |
| Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population) | 0/244 (0%) | 9/244 (3.7%) | 114/244 (46.7%) |
| Placebo (up to Week 16) (China Extension Population) | 0/11 (0%) | 0/11 (0%) | 8/11 (72.7%) |
| Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population) | 0/20 (0%) | 3/20 (15%) | 13/20 (65%) |
| Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population) | 0/20 (0%) | 3/20 (15%) | 16/20 (80%) |
| Event | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population) | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) | BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population) | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population) |
|---|---|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/126 | 0/128 | 2/242 | 2/244 | 0/11 | 0/9 | 1/20 | 1/20 |
| Cervical dysplasiaReproductive system and breast disorders | 0/126 | 0/128 | 0/242 | 0/244 | 0/11 | 0/9 | 1/20 | 1/20 |
| Abortion inducedReproductive system and breast disorders | 0/126 | 0/128 | 0/242 | 0/244 | 0/11 | 0/9 | 1/20 | 1/20 |
| Abdominal adhesionsGastrointestinal disorders | 1/126 | 0/128 | 0/242 | 0/244 | 0/11 | 0/9 | 0/20 | 0/20 |
| Deafness unilateralEar and labyrinth disorders | 0/126 | 0/128 | 1/242 | 1/244 | 0/11 | 0/9 | 0/20 | 0/20 |
| Tonsillitis bacterialInfections and infestations | 0/126 | 0/128 | 1/242 | 1/244 | 0/11 | 0/9 | 0/20 | 0/20 |
| ErysipelasInfections and infestations | 0/126 | 0/128 | 1/242 | 1/244 | 0/11 | 0/9 | 0/20 | 0/20 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/126 | 0/128 | 1/242 | 1/244 | 0/11 | 0/9 | 0/20 | 0/20 |
| Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/126 | 0/128 | 1/242 | 1/244 | 0/11 | 0/9 | 0/20 | 0/20 |
| Intentional self-injuryPsychiatric disorders | 0/126 | 0/128 | 1/242 | 1/244 | 0/11 | 0/9 | 0/20 | 0/20 |
| Event | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (Week 16 up to Week 52) (Global Population) | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) | BKZ 160 mg Q4W (Week 16 up to Week 52) (China Extension Population) | Overall Period (up to Week 48 + 20 Weeks SFU): Bimekizumab 160 mg Q4W (China Population) |
|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 10/126 | 9/128 | 15/242 | 23/244 | 3/11 | 1/9 | 3/20 | 4/20 |
| Liver function test abnormalInvestigations | 0/126 | 0/128 | 1/242 | 1/244 | 0/11 | 2/9 | 1/20 | 3/20 |
| Corona virus infectionInfections and infestations | 1/126 | 1/128 | 17/242 | 17/244 | 0/11 | 0/9 | 4/20 | 4/20 |
| Injection site painGeneral disorders | 2/126 | 2/128 | 3/242 | 5/244 | 2/11 | 0/9 | 0/20 | 0/20 |
| NasopharyngitisInfections and infestations | 6/126 | 13/128 | 18/242 | 30/244 | 1/11 | 0/9 | 0/20 | 0/20 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/126 | 2/128 | 1/242 | 3/244 | 0/11 | 1/9 | 1/20 | 1/20 |
| Vision blurredEye disorders | 0/126 | 0/128 | 0/242 | 0/244 | 0/11 | 1/9 | 0/20 | 1/20 |
| DiarrhoeaGastrointestinal disorders | 2/126 | 3/128 | 6/242 | 9/244 | 0/11 | 1/9 | 0/20 | 1/20 |
| GastritisGastrointestinal disorders | 1/126 | 0/128 | 0/242 | 0/244 | 0/11 | 1/9 | 0/20 | 1/20 |
| Abdominal painGastrointestinal disorders | 1/126 | 0/128 | 7/242 | 7/244 | 0/11 | 1/9 | 0/20 | 1/20 |
Baseline Characteristics refer to the Randomized Set which consisted of all randomized study participants. AS0010 China Extension Participants refer to an additional randomized set recruited in China after the closure of the global study recruitment.
| Age, Customized(Participants) | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) | Total |
|---|---|---|---|---|---|
| 18 - <65 | 123 | 125 | 11 | 9 | 268 |
| 65 - <85 | 3 | 3 | 0 | 0 | 6 |
| >= 85 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) | Total |
|---|---|---|---|---|---|
| Female | 61 | 55 | 7 | 2 | 125 |
| Male | 65 | 73 | 4 | 7 | 149 |
| Race/Ethnicity, Customized(Participants) | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) | Total |
|---|---|---|---|---|---|
| Asian | 13 | 15 | 11 | 9 | 48 |
| Black | 1 | 2 | 0 | 0 | 3 |
| White | 110 | 109 | 0 | 0 | 219 |
| Other/Mixed | 1 | 1 | 0 | 0 | 2 |
| Missing | 1 | 1 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Placebo (up to Week 16) (Global Population) | Bimekizumab 160 mg Q4W (up to Week 16) (Global Population) | Placebo (up to Week 16) (China Extension Population) | Bimekizumab 160 mg Q4W (up to Week 16) (China Extension Population) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 0 | 0 | 5 |
| Not Hispanic or Latino | 122 | 125 | 11 | 9 | 267 |
| Missing | 1 | 1 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Apr 2019 to primary completion in Jun 2022, 38 months.
Results were first posted in Nov 2024, 2 years 4 months after primary completion. A results delay was requested in Jun 2023.
Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 38 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab